<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1336</ReferenceId>
        <DateLastUpdated>2018-10-16-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11932390</PubmedId>
            <Abstract>The phenomenon whereby the host immune system responds to only a few of the many possible epitopes in a foreign protein is termed immunodominance. Immunodominance occurs not only during microbial infection but also following vaccination, and clarification of the underlying mechanism may permit the rational design of vaccines which can circumvent immunodominance, thereby inducing responses to all epitopes, dominant and subdominant. Here, we show that immunodominance affects DNA vaccines and that the effects can be avoided by the simple expedient of epitope separation. DNA vaccines encoding isolated dominant and subdominant epitopes induce equivalent responses, confirming a previous demonstration that coexpression of dominant and subdominant epitopes on the same antigen-presenting cell (APC) is central to immunodominance. We conclude that multiepitope DNA vaccines should comprise a cocktail of plasmids, each with its own epitope, to allow maximal epitope dispersal among APCs. In addition, we demonstrate that subdominant responses are actively suppressed by dominant CD8(+) T-cell responses and that gamma interferon (IFN-gamma) is required for this suppression. Furthermore, priming of CD8(+) T cells to a single dominant epitope results in strong suppression of responses to other normally dominant epitopes in immunocompetent mice, in effect rendering these epitopes subdominant; however, responses to these epitopes are increased 6- to 20-fold in mice lacking IFN-gamma. We suggest that, in agreement with our previous observations, IFN-gamma secretion by CD8(+) T cells is highly localized, and we propose that its immunosuppressive effect is focused on the APC with which the dominant CD8(+) T cell is in contact.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>4251-9</ArticlePages>
            <ArticleTitle>Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Rodriguez</LastName>
                    <ForeName>Fernando</ForeName>
                </Author>
                <Author>
                    <LastName>Harkins</LastName>
                    <ForeName>Stephanie</ForeName>
                </Author>
                <Author>
                    <LastName>Slifka</LastName>
                    <ForeName>Mark K</ForeName>
                </Author>
                <Author>
                    <LastName>Whitton</LastName>
                    <ForeName>J Lindsay</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Immunodominant Epitopes;Vaccines, DNA;Viral Vaccines;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigen Presentation; CD8-Positive T-Lymphocytes(immunology); Epitopes, T-Lymphocyte(genetics; immunology); Immunization; Immunodominant Epitopes(drug effects; genetics; immunology); Interferon-gamma(genetics; physiology); Lymphocytic Choriomeningitis(immunology; prevention &amp; control); Lymphocytic choriomeningitis virus(genetics; immunology); Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Vaccines, DNA(administration &amp; dosage; immunology); Viral Vaccines(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>76</Volume>
                <Issue>9</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 118-126</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RPQASGVYM</LinearSequence>
                        <StartingPosition>118</StartingPosition>
                        <EndingPosition>126</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 1, M&amp;M</LocationOfData>
                <EpitopeId>55289</EpitopeId>
                <ReferenceStartingPosition>118</ReferenceStartingPosition>
                <ReferenceEndingPosition>126</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>21209</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RPQASGVYM</LinearSequence>
                                            <StartingPosition>118</StartingPosition>
                                            <EndingPosition>126</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 5 days after  i.p.LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The epitope minigene used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus and expressed as a fusion protein with ubiquitin in the pCMV expression vector. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <Plasmid>
                                    <SubType>Plasmid</SubType>
                                </Plasmid>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>15.0</QuantitativeMeasurement>
                            <AssayComments>Mice immunized with a plasmid DNA with epitope minigene and infected 6 weeks later with LCMV generate significant levels of IFN-g+ CD8+ cells in response to stimulation with LCMV-infected or source protein transfected cells, while less than 5% of cells are generated in mice primed with the subdominant epitope N313-322, showing that perhaps a competition for MHC is occurring between this two Ld-restricted epitopes  that favor presentation of the immunodominant one. However, further experiments when cells are transfected with the source protein with NP118-126 deleted, the same low frequency of NP131-122-specific cells is seen. The low response to this epitope is not due to MHC competition with this immunodominant epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2, 3, and 4</LocationOfData>
                        <TCellId>21208</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RPQASGVYM</LinearSequence>
                                            <StartingPosition>118</StartingPosition>
                                            <EndingPosition>126</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 days after DNA vaccination or at different times after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV. The epitope minigene used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus and expressed as a fusion protein with ubiquitin in the pCMV expression vector. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>1.3</QuantitativeMeasurement>
                            <AssayComments>Mice immunized with a plasmid DNA encoding this immunodominant epitope minigene generate epitope specific IFN-g+ CD8+ cells, adding up to 1.3% and a similar responses is obtained with the subdominant epitope NP313-322 in mice immunized with that epitope minigene. The proportion is lower but still significant if mice are doubly immunized with plasmids encoding each of the minigenes, where the responses against both epitopes are comparable, showing that immunodominance can be largely circumvented by physically separating the sequences, even if both vaccines are administered simultaneously. In mice primed with this epitope minigene and infected 6 weeks later with LCMV an expansion of epitope specific memory cells adding up to ~35% recognizing peptide loaded cells and ~20% recognizing minigene transfected cells is obtained, showing that mice can be effectively primed to this epitope. The expansion of cells recognizing the subdominant epitope in mice primed with that epitope is slower and in doubly primed mice, with both minigenes administered separately but simultaneously, the expansion of the subdominant epitope response is abolished, implying that the expansion of the NP313-322-specific memory cells was inhibited by the rapid virus-driven expansion of the dominant memory T cells directed to this epitope. This effect is not to be related to the antigenic load following challenge, since all mice (single or doubly vaccinated) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>21206</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:12155</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2x10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested  7 (acute response) or 50 (memory population) days after infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>38.0</QuantitativeMeasurement>
                            <AssayComments>IFN-g+ CD8+ cells reactive towards this immunodominant epitope from the source protein are seen in the primary response after lymphocytic choriomeningitis virus infection (LCMV), adding up to 38% of the CD8+ cells and in the memory population the proportion is of 16%. These percentages are significantly higher than the cells reactive with the subdominant epitope NP313-322.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>21207</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 days after immunization. The source protein ORF is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>1.5</QuantitativeMeasurement>
                            <AssayComments>Mice immunized with a plasmid DNA encoding source protein generate 1.5% epitope specifc IFN-g+ CD8+ cells at day 15 post immunization, while cells reactive to the subdominant epitope NP313-322 are not detectable, suggesting that immunodominance also affects DNA vaccines.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>21210</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000009</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested at different times after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The source protein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector. Immunized animal are knockouts lacking IFN-g.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>18.1</QuantitativeMeasurement>
                            <AssayComments>GKO BALB/c mice (lacking endogenous IFN-g production) immunized with a plasmid DNA encoding source protein as a fusion with ubiquitin and infected 6 weeks later with LCMV develop similar proportion of TNF+ CD8+ cells specific for this immunodominant epitope than wild type BALB/c mice at all time points, from 4 to 24 days post-immunization. Reponses directed to the subdominant epitope NP313-322 are enhanced in GKO mice, implying that IFN-g plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 313-322</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WPYIACRTSI</LinearSequence>
                        <StartingPosition>313</StartingPosition>
                        <EndingPosition>322</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 1, M&amp;M</LocationOfData>
                <EpitopeId>72975</EpitopeId>
                <ReferenceStartingPosition>313</ReferenceStartingPosition>
                <ReferenceEndingPosition>322</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>21216</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 days after immunization. The source protein ORF is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 313-322</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WPYIACRTSI</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>322</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Mice immunized with a plasmid DNA encoding the source protein fail to generate reactive IFN-g+ CD8+ cells at day 15 post immunization, while cells reactive to the immunodominant epitope NP118-126 add up to a 1.5%, suggesting that immunodominance also affects DNA vaccines.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>21219</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000009</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested at different times after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV. The source protein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector. Immunized animal are knockouts lacking IFN-g.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 313-322</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WPYIACRTSI</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>322</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>11.8</QuantitativeMeasurement>
                            <AssayComments>GKO BALB/c mice (lacking endogenous IFN-g production) immunized with a plasmid DNA encoding source protein and infected 6 weeks later with LCMV develop higher proportion (18.1%) of TNF+ CD8+ cells specific for this subdominant epitope than wild type BALB/c mice (where the proportion is 2.1%). This elevated level of response is seen at all time points, from 4 to 24 days post-immunization, implying that IFN-g plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>21218</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WPYIACRTSI</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>322</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 5 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The epitope minigene used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus and expressed as a fusion protein with ubiquitin in the pCMV expression vector. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <Plasmid>
                                    <SubType>Plasmid</SubType>
                                </Plasmid>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>5.0</QuantitativeMeasurement>
                            <MeasurementInequality>&lt;</MeasurementInequality>
                            <AssayComments>Mice immunized with a plasmid DNA with epitope minigene as a fusion protein with ubiquitin and infected 6 weeks later with LCMV generate low levels of IFN-g+ CD8+ cells in resposne to stimulation with LCMV-infected or source protein transfected cells, while  ~40% of cells are obtained with peptide loaded cells, showing that perhaps a competition for MHC is occurring with the Ld-restricted dominant epitope NP118-126. However, when cells are transfected with the source protein with NP118-126 deleted, the same low frequency is seen. Thus, the low response to this epitope is not due to MHC competition with the immunodominant epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2, 3, and 4</LocationOfData>
                        <TCellId>21217</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WPYIACRTSI</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>322</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 days after DNA vaccination or at different times after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV. The epitope minigene used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus and expressed as a fusion protein with ubiquitin in the pCMV expression vector. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 313-322</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WPYIACRTSI</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>322</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>1.1</QuantitativeMeasurement>
                            <AssayComments>Mice immunized with a plasmid DNA encoding this subdominant epitope minigene generate epitope specific IFN-g+ CD8+ cells, adding up to 1.1%, similar to the responses against immunodominant epitope NP118-126 in mice immunized with that epitope minigene. The proportion is lower, but still significant if mice are doubly immunized with plasmids encoding each of the minigenes, where the responses against both epitopes are comparable, showing that immunodominance can be largely circumvented by physically separating the sequences, even if both vaccines are administered simultaneously. In mice primed with this epitope minigene and infected 6 weeks later with LCMV an expansion of epitope specific memory cells adding up to ~40% recognizing peptide loaded cells and ~25% recognizing minigene transfected cells is obtained, showing that mice can be effectively primed to this epitope. The expansion of cells recognizing the immunodominant epitope in mice primed with that epitope is shown to be more rapid, while in doubly primed mice, with both minigenes administered separately but simultaneously, the expansion of the subdominant epitope response is abolished, implying that the expansion of the DNA-primed NP313-322-specific memory cells was inhibited by the rapid virus-driven expansion of the dominant memory T cells. This effect is shown not to be related with the antigenic load following challenge, since all the mice (single or doubly vaccinated) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>21215</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:12155</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2x10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested  7 (acute response) or 50 (memory population) days after infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>126</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 313-322</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WPYIACRTSI</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>322</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.1</QuantitativeMeasurement>
                            <AssayComments>IFN-g+ CD8+ cells reactive towards this subdominant epitope from the source protein are seen in the primary response after lymphocytic choriomeningitis virus infection (LCMV), adding up to 2.1% of the CD8+ cells and in the memory population the proportion is of 0.5%. These percentages are significantly lower than the cells reactive to the immunodominant epitope NP118-126.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 396-404</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FQPQNGQFI</LinearSequence>
                        <StartingPosition>396</StartingPosition>
                        <EndingPosition>404</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors' communication</LocationOfData>
                <EpitopeId>17516</EpitopeId>
                <ReferenceStartingPosition>396</ReferenceStartingPosition>
                <ReferenceEndingPosition>404</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21228</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 or 22 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The source protein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 396-404</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FQPQNGQFI</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>404</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>14.7</QuantitativeMeasurement>
                            <AssayComments>C57BL/6 mice immunized with a plasmid DNA encoding source protein and infected 6 weeks later with LCMV have a significant expansion of memory CD8+ TNF+ cells towards this dominant epitope both at 15 (14.7%) or 22 (23.8%) days after infection. GKO C57BL/6 mice (lacking endogenous IFN-g production) develop a lower proportion of TNF+ CD8+ cells (10.5 and 6.4% at day 15 and 22 post infection, respectively), and their primary responses against other immunodominant epitopes are augmented, implying that the presence of memory cells specific for a dominant epitope may abolish primary responses to other dominant epitopes, but this effect is not seen in the absence of IFN-g. INF-g thus plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21236</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000095</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 or 22 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The source protein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector.  Immunized animal are knockouts lacking IFN-g.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 396-404</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FQPQNGQFI</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>404</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>10.5</QuantitativeMeasurement>
                            <AssayComments>GKO C57BL/6 mice (lacking endogenous IFN-g production) immunized with a plasmid DNA encoding source protein and infected 6 weeks later with LCMV have a lower level of expansion of memory CD8+ TNF+ cells towards this dominant epitope than WT C57BL/6 mice (10.5 vs. 14.7 at day 15 post infection, 6.4 vs. 23.8 at day 22). The primary responses against other immunodominant epitopes are augmented in GKO mice, implying that the presence of memory cells specific for a dominant epitope may abolish primary responses to other dominant epitopes, but this effect is not seen in the absence of IFN-g. INF-g thus plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP276-286</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                        <StartingPosition>276</StartingPosition>
                        <EndingPosition>286</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors' communication</LocationOfData>
                <EpitopeId>58282</EpitopeId>
                <ReferenceStartingPosition>276</ReferenceStartingPosition>
                <ReferenceEndingPosition>286</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21232</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000095</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 or 22 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The Nucleoprotein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector. Immunized animal are knockouts lacking IFN-g.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP276-286</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>286</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>5.9</QuantitativeMeasurement>
                            <AssayComments>GKO C57BL/6 mice (lacking endogenous IFN-g production) immunized with a plasmid DNA encoding a different protein (Nucleoprotein) from LCMV and infected 6 weeks later with LCMV develop a stronger primary response to this dominant epitope from Glycoprotein,  than wild type C57BL/6 mice, with a higher proportion of specific TNF+ CD8+ cells (5.9% vs. 0.3%). This elevated level of response is seen at 15 and 22 days post LCMV infection. Since primary responses against this immunodominant epitope are inhibited by the presence of memory cells specific for another dominant epitope and this effect is not seen in the absence of IFN-g, IFN-g thus plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21231</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 or 22 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The Nucleoprotein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP276-286</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>286</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.3</QuantitativeMeasurement>
                            <AssayComments>C57BL/6 mice immunized with a plasmid DNA encoding a different protein (Nucleoprotein) from LCMV and infected 6 weeks later with LCMV fail to develop a strong primary response towards this dominant epitope from Glycoprotein, while GKO C57BL/6 mice (lacking endogenous IFN-g production) develop a higher proportion of TNF+ CD8+ cells (5.9% vs. 0.4%) specific for this epitope. This elevated level of response is seen at 15 and 22 days post LCMV infection. Since primary responses against this immunodominant epitope are inhibited by the presence of memory cells specific for another dominant epitope and this effect is not seen in the absence of IFN-g, INF-g thus plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP33-41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors' communication</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>41</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21233</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 or 22 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The Nucleoprotein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP33-41</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.4</QuantitativeMeasurement>
                            <AssayComments>C57BL/6 mice immunized with a plasmid DNA encoding a different protein (Nucleoprotein) from LCMV and infected 6 weeks later with LCMV fail to develop a strong primary response towards this dominant epitope from Glycoprotein, while GKO C57BL/6 mice (lacking endogenous IFN-g production) develop a higher proportion of TNF+ CD8+ cells (4.4% vs. 0.4%) specific for this epitope. This elevated level of response is seen at 15 and 22 days post LCMV infection. Since primary responses against this immunodominant epitope are inhibited by the presence of memory cells specific for another dominant epitope and this effect is not seen in the absence of IFN-g, INF-g thus plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all  mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21234</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000095</OrganismId>
                                <Age>6-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 100 μg DNA, 50 μg in each anterior tibial muscle.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Splenocytes were harvested 15 or 22 days after i.p. LCMV infection (6 weeks after DNA immunization) with 2x10&lt;sup&gt;5&lt;/sup&gt; PFU. The Nucleoprotein ORF used as immunogen is under the control of the immediate-early promoter of human cytomegalovirus in the pCMV expression vector. Immunized animal are knockouts lacking IFN-g.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP33-41</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>4.4</QuantitativeMeasurement>
                            <AssayComments>GKO C57BL/6 mice (lacking endogenous IFN-g production) immunized with a plasmid DNA encoding a different protein (Nucleoprotein) from LCMV and infected 6 weeks later with LCMV develop a stronger primary response to this dominant epitope from Glycoprotein,  than wild type C57BL/6 mice, with a higher proportion of specific TNF+ CD8+ cells (4.4% vs. 0.4%). This elevated level of response is seen at 15 and 22 days post LCMV infection. Since primary responses against this immunodominant epitope are inhibited by the presence of memory cells specific for another dominant epitop and this effect is not seen in the absence of IFN-g, IFN-g thus plays an important role in the establishment of immunodominance, probably by suppression of the subdominant responses by IFN-g secreted by dominant CD8+ T cells. This effect is shown not to be related with the antigenic load following challenge, since all mice (WT and GKO) clear the infection similarly and completely in 4 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

